Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 18/20 | 0.62 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15471436 | 0.91 | PIK3CD (0.75) | PIK3CDKDM4EALDH1A1GAAMAPK1 | |
| SCHEMBL4180797 | 0.81 | PIK3CD (0.55) | PIK3CDKDM4EALDH1A1GAAMAPK1 | |
| SCHEMBL1887223 | 0.78 | PIK3CD (0.67) | PIK3CDMAPK1 | |
| SCHEMBL4563865 | 0.74 | PIK3CD (0.48) | PIK3CDKDM4EALDH1A1GAAMAPK1 | |
| SCHEMBL788676 | 0.74 | PIK3CD (0.58) | PIK3CD | |
| SCHEMBL4189198 | 0.73 | PIK3CD (0.50) | PIK3CD | |
| SCHEMBL4174263 | 0.72 | PIK3CD (0.53) | PIK3CDALDH1A1 | |
| SCHEMBL17928662 | 0.70 | PIK3CD (0.46) | PIK3CDKDM4EALDH1A1GAAMAPK1 | |
| SCHEMBL6989437 | 0.70 | PIK3CD (0.58) | PIK3CDKDM4EALDH1A1GAAMAPK1 | |
| SCHEMBL4184546 | 0.69 | PIK3CD (0.55) | PIK3CDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10053470-B2 | Inhibitors of PI3K-delta and methods of their use and manufacture | EXELIXIS, INC. (US) | 2018-08-21 | — | — | US | claimed |
| US-20140303151-A9 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-10-09 | — | — | US | claimed |
| US-20140045825-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-02-13 | — | — | US | claimed |
| EP-2616442-A1 | INHIBITORS OF PI3K-DELTA AND METHODS OF THEIR USE AND MANUFACTURE | Exelixis, Inc. (US) | 2013-07-24 | — | — | EP | claimed |
| WO-2012037204-A1 | INHIBITORS OF PI3K-DELTA AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | claimed |
| US-10053470-B2 | Inhibitors of PI3K-delta and methods of their use and manufacture | EXELIXIS, INC. (US) | 2018-08-21 | — | — | US | disclosed |
| EP-2616442-B1 | INHIBITORS OF PI3K-DELTA AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-20170226131-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-9670212-B2 | Inhibitors of PI3K-delta and methods of their use and manufacture | EXELIXIS, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20140303151-A9 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140045825-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| EP-2616442-A1 | INHIBITORS OF PI3K-DELTA AND METHODS OF THEIR USE AND MANUFACTURE | Exelixis, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012037204-A1 | INHIBITORS OF PI3K-DELTA AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303151-A9 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | PIK3CD, PIK3CA, PIK3R5 | PIK3CD 1/4885PIK3CG 4/4885KDM4E 2378/4885 |
| US-20170226131-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | PIK3CD, PIK3CA, PIK3R5 | PIK3CD 1/4885PIK3CG 4/4885KDM4E 2388/4885 |
| US-10053470-B2 | Inhibitors of PI3K-delta and methods of their use and manufacture | PIK3CD, PIK3CA, PIK3R5 | PIK3CD 1/4885PIK3CG 4/4885KDM4E 2388/4885 |
| US-20140045825-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | PIK3CD, PIK3CA, PIK3R5 | PIK3CD 1/4885PIK3CG 4/4885KDM4E 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.